We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Protect and preserve cells without compromising functionality with the cutting-edge PRIME-XV FreezIS Cryopreservation Media Portfolio. PRIME-XV FreezIS is available in DMSO-Free and DMSO-containing formulations that are optimized to freeze a variety of cell types, including human mesenchymal stromal/stem cells (MSCs), hematopoietic stem cells (HSCs), and human T cells from peripheral blood mononuclear cells (PBMCs). The slow freezing process minimizes damage from cold shock with validation post-thaw for cell markers, viability, and fold expansion—all while giving you the options you need to get therapies to patients, faster.
Accelerate life-changing therapies to market: Now available as an excipient* and non-excipient medium
The cutting-edge formulations of PRIME-XV FreezIS Cryopreservation Media Portfolio are optimized to protect and preserve cells without compromising functionality no matter how manufacturing needs change.
Determine the right PRIME-XV FreezIS media formulation for manufacturing success
| Product | Customer use | Contains DMSO | DMSO-free | Eliminates post-thaw wash step | Reduces vein-to-vein time |
| PRIME-XV FreezIS | Ancillary | ✓ | |||
| PRIME-XV FreezIS DMSO-Free | Ancillary | ✓ | |||
| PRIME-XV FreezIS (EX) | Excipient | ✓ | ✓ | ✓ | |
| PRIME-XV FreezIS DMSO-Free (EX) | Excipient | ✓ | ✓ | ✓ |
*Testing for individual applications is the responsibility of the customer. Product can be used as excipient, which means that the cells and media combined are treated as one product that is to be approved by the FDA.
